Reported 2 months ago
In a recent discussion, Maurits Pot, CEO of Tema ETFs, highlights Eli Lilly and Novo Nordisk as leading GLP-1 manufacturers with significant potential for growth. He anticipates increasing competition in the market as innovations emerge, including oral treatments and varied dosage approaches, with contenders such as Amgen and Alnylam possibly reshaping the landscape. This indicates a promising future for the GLP-1 sector beyond current leaders.
Source: YAHOO